Table 1. Serum samples used in the study.

1A: Sample groups used for autoantibody discovery. 1B: Sample groups used for autoantibody pre-validation studies. 1C: Sample groups used for autoantibody prevalidation studies.

Table 1A. Sample groups used for autoantibody discovery
Group	Clinical Status	Number	TNM	Stage	CA125	Age
1	Healthy female subjects	20	NA	NA	NA	45-75
2	Benign pelvic mass or endometriosis	20	NA	NA	NA	45-75
3	Stage l-IV ovarian cancer:	20	NA	I-IV	3.924≤x≤3924	36≤x≤78
	1. Clear cell carcinoma and endometrioid adenocarcinoma		T1cN0M0	I	10.31	78
	2. Endometrioid adenxarcinoma		T1cN0M0	I	96	51
	3. Serous adenocarcinoma		T1cN0M0	I	439.6	71
	4. Serous adenocarcinoma		T1aN0M0	I	165	57
	5. Mucinous adenocarcinoma		T1cN0M0	I	49	62
	6. Serous adenocarcinoma		T1cN0M0	I	312	47
	7. Serous papillary adenocarcinoma		T1aN0M0	I	92	54
	8. Serous adenocarcinoma		T1cN0M0	I	218	48
	9. Endometrioid adenocarcinoma		T1cN0M0	I	144	44
	10. Serous adenocarcinoma		T1cN0M0	I	165	66
	11. Endometrioid cystadenocarcinoma		T2bN0M0	II	112	66
	12. Endometrioid adenocarcinoma		T2aN0M0	II	166	41
	13. Serous adenocarcinoma		T2bN0M0	II	88	68
	14. Endometrioid adenocarcinoma		T2aN0M0	II	480	56
	15. Serous adenocarcinoma		T3cN0M0	III	605	72
	16. Serous adenocarcinoma		T3aN0MO	III	384	74
	17. Clear cell carcinoma		T3cNIM0	III	524	68
	18. Serous adenocarcinoma		T3cN0M1	IV	3924	64
	19. Clear cell cystadenocarcinoma		T3cN0M1	IV	3.924	36
	20. Endometrioid adenocarcinoma		T3cN1M1	IV	46	63

Table 1B. Sample groups used for autoantibody pre-validation studies
Group	Clinical Status	Number
1	Healthy female subjects	20
2	Benign pelvic mass	20
3	Stage I ovarian cancer with various levels of CA-125 (10-439)	20
4	Stage II-IV ovarian cancer with various levels of CA-125 (46-3,924)	20

Table 1C. Sample groups used for autoantibody pre-validation
Group	Clinical status	CA-125 levels	Number
1	Ovarian cancer	Normal (<5)	5
2	Ovarian cancer	Low (10.31-49)	10
3	Ovarian cancer	Medium (55.8-96)	20
4	Ovarian cancer	High (112-480)	20
5	Ovarian cancer	Very-high (524-23422)	20
6	Non-ovarian cancer	(17.3-640)	5